What is Metolazone?
Metolazone is a potent thiazide-like diuretic that acts primarily at the cortical diluting site of the renal tubule to inhibit sodium reabsorption, and it is most commonly used as a "last resort" agent added to loop diuretics in severe heart failure with refractory fluid retention. 1
Drug Classification and Mechanism
Metolazone is a quinazoline-class diuretic with properties similar to thiazide diuretics, but with important distinctions 1:
- Primary site of action: Cortical diluting site in the distal tubule
- Secondary action: Proximal convoluted tubule (to a lesser extent)
- Does NOT inhibit carbonic anhydrase (unlike some other diuretics)
- Results in approximately equivalent excretion of sodium and chloride ions
- Increases potassium excretion through enhanced sodium delivery to distal tubular exchange sites
Key Pharmacological Properties
Critical distinguishing feature: Unlike standard thiazides, metolazone produces diuresis even when glomerular filtration rate (GFR) is below 20 mL/min 1. This makes it uniquely valuable in advanced heart failure with significant renal impairment.
Pharmacokinetics 1, 2:
- Onset of action: Within 1 hour of administration
- Duration: May persist 24 hours or more (12-24 hours typical)
- Peak blood levels: Approximately 8 hours after dosing
- Absorption: Slow and sometimes erratic, particularly with reduced renal perfusion in heart failure
- Metabolism: Minimal; most excreted unchanged in urine
- Food effect: Increases time to maximum concentration (tmax) by approximately 100%
Clinical Indications and Positioning
Primary Use in Heart Failure
Metolazone is reserved for severe chronic heart failure with diuretic resistance 3. The guidelines are consistent across multiple societies:
- First-line therapy: Loop diuretics (furosemide, bumetanide, torsemide)
- Insufficient response: Increase loop diuretic dose or administer twice daily
- Persistent fluid retention: Add metolazone with frequent measurement of creatinine and electrolytes 3
The 2013 ACC/AHA guidelines 4 and 1995 ACC/AHA guidelines 5 specifically recommend metolazone when diuretic resistance develops, noting it can be "often effective" when combined with loop diuretics.
Synergistic Effect with Loop Diuretics
A critical clinical pearl: Metolazone combined with furosemide produces marked diuresis in patients refractory to maximum doses of either drug alone 1. The mechanism of this synergistic interaction remains unknown, but it is clinically well-established 3, 6.
Dosing Recommendations
Standard Dosing 3, 4, 7:
Initial dose: 2.5 mg orally once daily
Maximum dose: 10-20 mg daily (guidelines vary: European guidelines state 10 mg 3; US guidelines allow up to 20 mg 4, 7)
Practical Dosing Strategy 5:
For outpatient management of weight gain:
- Add 2.5 mg metolazone for 2-3 days to the loop diuretic
- Return to usual maintenance loop diuretic dose when weight stabilizes
- Patients should weigh themselves daily and maintain a weight log
Important caveat: The 1995 ACC/AHA guidelines 5 and 2001 European guidelines 3 emphasize that metolazone should be used cautiously, as severe electrolyte and volume depletion can occur, potentially warranting hospital admission in the presence of hypotension, azotemia, oliguria, or ascites.
Major Adverse Effects and Monitoring
Side Effects 3:
- Hypokalemia (most common and clinically significant)
- Hypomagnesemia
- Hyponatremia
- Hyperuricemia
- Glucose intolerance
- Acid-base disturbances
Required Monitoring 3:
When initiating or combining with loop diuretics, measure creatinine and electrolytes:
- Every 5-7 days after initiation until values are stable
- Then every 3-6 months during maintenance therapy
The 2019 ACC expert consensus 7 recommends at least daily electrolyte monitoring during hospitalization when using combination diuretic therapy.
Critical Safety Warnings
Volume Depletion Risk 5, 8, 9:
Severe electrolyte and volume depletion can occur when metolazone is combined with loop diuretics 5. Hospital admission may be warranted when combining these agents in patients with:
- Hypotension
- Azotemia
- Oliguria
- Ascites
Hyperkalemia Risk with ACE Inhibitors:
Dangerous hyperkalemia may occur when ACE inhibitors are used with potassium-sparing agents or large doses of oral potassium 5. While metolazone itself causes hypokalemia, the overall electrolyte management becomes complex in heart failure patients on multiple medications.
Dosing Caution 10:
If excessive diuresis occurs with metolazone and loop diuretic combination, BOTH drugs should be stopped temporarily—not simply dose-reduced. This is a critical safety point, as the temptation to reduce doses may not adequately control an active, excessive diuresis.
Availability and Formulation
Important limitation: Metolazone is not available in all European countries 3. In the United States, it is available as oral tablets in 2.5 mg, 5 mg, and 10 mg strengths 1. There is currently no FDA-approved intravenous formulation, though research into IV emulsions is ongoing 11.
Clinical Evidence Base
A notable weakness in the evidence: The 2005 observational study 12 found that available information on metolazone use in heart failure is based on studies containing less than 250 patients in total. Despite this limited evidence base, metolazone is widely used and recommended in major guidelines, reflecting its clinical utility in refractory cases where few alternatives exist.
The same study 12 reported that in contemporary outpatients with refractory systolic heart failure, low-dose metolazone (≤5 mg) on top of oral loop diuretics was effective and relatively safe, though clinically important hypokalemia (<2.5 mM) or hyponatremia (<125 mM) occurred in 10% of treatment episodes.